DIPSS Plus Score for Prognosis in Myelofibrosis

Estimate prognosis in myelofibrosis.

The global unit selector only affects unanswered questions
1.Age?
2.Constitutional Symptoms?
3.WBC Count
4.Hemoglobin?
5.Blasts in Peripheral Blood?
6.Karyotype?
7.Transfusion Dependency?
8.Platelets <100 x 10⁹/L?
Created by

1. Age?

Created by
0/8 completed

About this Calculator

The DIPSS was proposed and validated by Passamonti et al to estimate prognosis in myelofibrosis.

The DIPSS plus score further refines the prior prognostic scoring system with the addition of DIPSS-independent risk factors, including karyotype, transfusion dependency and platelet count. The score was developed and validated by Gangat et al.

Prognosis based on 6 point scoring system:

  • If score is 0: Patient is considered "low risk" according to the DIPSS plus system. Median survival is estimated to be 180 months
  • If score is 1: Patient is considered "intermediate-1 risk" according to the DIPSS plus system. Median survival is estimated to be 80 months
  • If score is 2-3: Patient is considered "intermediate-2 risk" according to the DIPSS plus system. Median survival is estimated to be 35 months
  • If score is 4 or more: Patient is considered "high risk" according to the DIPSS plus system. Median survival is estimated to be 16 months
Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.